Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Boosted by Heritage Wealth Management LLC

Heritage Wealth Management LLC increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 37.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,272 shares of the specialty pharmaceutical company’s stock after purchasing an additional 616 shares during the period. Heritage Wealth Management LLC’s holdings in Supernus Pharmaceuticals were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of SUPN. MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income acquired a new position in Supernus Pharmaceuticals during the third quarter worth about $8,832,000. Victory Capital Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 35.7% during the 3rd quarter. Victory Capital Management Inc. now owns 866,750 shares of the specialty pharmaceutical company’s stock valued at $23,116,000 after buying an additional 227,872 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 63.9% during the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 522,260 shares of the specialty pharmaceutical company’s stock valued at $16,080,000 after buying an additional 203,554 shares during the last quarter. International Biotechnology Trust PLC acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $6,233,000. Finally, Nuveen Asset Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 59.0% during the 2nd quarter. Nuveen Asset Management LLC now owns 466,073 shares of the specialty pharmaceutical company’s stock valued at $14,351,000 after buying an additional 172,875 shares during the last quarter. Institutional investors own 99.63% of the company’s stock.

Shares of SUPN stock opened at $30.36 on Friday. The stock’s fifty day simple moving average is $30.73 and its 200 day simple moving average is $28.74. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.85 and a quick ratio of 2.59. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of 20.11 and a beta of 1.16. Supernus Pharmaceuticals, Inc. has a one year low of $23.15 and a one year high of $34.50.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Wednesday, November 3rd. The specialty pharmaceutical company reported $0.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.19. The business had revenue of $148.46 million for the quarter, compared to analyst estimates of $141.32 million. Supernus Pharmaceuticals had a return on equity of 10.56% and a net margin of 14.49%. During the same quarter in the previous year, the firm earned $0.74 EPS. On average, research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.12 earnings per share for the current year.

A number of research analysts recently weighed in on SUPN shares. Jefferies Financial Group started coverage on Supernus Pharmaceuticals in a research note on Wednesday, December 1st. They issued a “buy” rating and a $44.00 price objective on the stock. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $35.00 price target on the stock in a research report on Friday, January 7th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

See Also: What is the Stochastic Momentum Index (SMI)?

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.